Business
Change of Nominated Advisor
Change of Nominated Advisor.
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n21 June 2024\n \nScancell Holdings plc\n \n(\"Scancell\" or the \"Company\")\n \nChange of Nominated Advisor\n \nScancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that Panmure Gordon (UK) Limited has been appointed as the Company's Nominated Advisor with immediate effect and will continue as Joint Broker.\n \nThis announcement contains insider information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR)\n \n \n\n\n\n\nFor further information, please contact:\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n\nScancell Holdings plc\n\n\n+44 (0) 20 3709 5700\n\n\n\n\nProfessor Lindy Durrant, CEO\nDr Jean-Michel Cosséry, Non-Executive Chairman\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPanmure Gordon (UK) Limited (Nominated Advisor and Joint Broker)\n\n\n\n\n\n\n\nEmma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)\nRupert Dearden (Corporate Broking)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWG Partners LLP (Joint Broker)\n\n\n+44(0) 20 3705 9330\n\n\n\n\nDavid Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nICR Consilium\n\n\n+44 (0) 20 3709 5700\n\n\n\n\nMary-Jane Elliott/Angela Gray/Lindsey Neville\n\n\[email protected]\n \n\n\n\n\nAbout Scancell\n \nScancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.\n \nAdaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of p...